Heart Failure

Nearly a quarter of adults living with heart failure with reduced ejection fraction (HFrEF) are prescribed at least one pharmaceutical that could exacerbate their condition, according to a study published in the American Journal of Cardiology Feb. 10.

Optimizing hemodynamics for heart failure (HF) patients with continuous-flow left ventricular assist devices (LVADs) significantly reduces the rate of those patients’ hospital readmissions, according to a study published Feb. 1 in Circulation: Heart Failure.

Survival rates for patients treated with Abiomed’s Impella RP right ventricular assist device have been much lower in a postapproval study than they were during the device’s premarket clinical trials, the FDA said Feb. 4 in a letter to physicians.  

Current conversion ratios may be underestimating the long-term cardiotoxicity of common chemotherapy agents like mitoxantrone and overestimating the cardiovascular risk of anthracyclines like daunorubicin, researchers reported in JAMA Oncology Jan. 31.

Knowing he needed a new heart, Robert Montgomery, MD, saw an opportunity to practice what he preaches. So, the 58-year-old director of NYU Langone Health’s Transplant Institute accepted an organ from a heroin user who died of a drug overdose and had hepatitis C.

Patients with severe aortic regurgitation (AR) may be better off receiving valve operations before symptoms appear that “trigger” guideline recommendations for these surgeries, according to a new study in JACC: Cardiovascular Imaging.

Active cocaine users with heart failure with reduced ejection fraction (HFrEF) benefited from beta-blocker therapy in a recent study, seeing improved left ventricular ejection fraction (LVEF) and reduced rates of cocaine-related CV events despite long-standing worries that the treatment might exacerbate symptoms of HF.

The nature of caregiving means the caregiver-patient relationship is always changing, but continued support from a network of experts and dedication to mutuality and preparedness can ensure both patients and caregivers have a good quality of life (QoL), according to a study published Jan. 14 in Circulation: Cardiovascular Quality and Outcomes.

Two new lawsuits have been filed against Baylor St. Luke’s Medical Center, the fourth and fifth malpractice complaints involving heart transplants at the Houston hospital since the Houston Chronicle and ProPublica exposed problems with its transplant program last year.

Baylor St. Luke’s Medical Center appointed a new president and restructured other staff after an investigation from the Houston Chronicle and ProPublica found mistakes at the Houston-based hospital’s heart transplant center led to patient deaths.

Public health insurance programs are covering an increasing number of heart transplant surgeries in the U.S., recent research suggests, meaning the outcomes of such procedures could hinge on decisions made by the federal government.

Tafamidis, Pfizer’s treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), has been granted a priority review designation from the FDA, potentially speeding its path to approval.